Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: Retrospective study

Biomedicine and Pharmacotherapy

Volumn 61, Issue 6, 2007, Pages 370-376

  Astegiano, M ^a   Pagano, N ^a   Sapone, N ^a   Simondi, D ^a   Bertolusso, L ^a   Bresso, F ^b   Demarchi, B ^a   Pellicano, R ^a   Bonardi, R ^a   Marconi, S ^c   Rizzetto, M ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b Sophiahemmet AB   (Sweden)

^c CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

Beclomethasone dipropionate coated tablets; Crohn's disease; Ileum; Inflammatory bowel disease; Right colon

Indexed keywords

BECLOMETASONE DIPROPIONATE; CLIPPER; GLUCOCORTICOID; UNCLASSIFIED DRUG;

ACNE; ADOLESCENT; ADRENAL SUPPRESSION; ADULT; AGED; ARTICLE; CANCER REGRESSION; CATARACT; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CUSHINGOID SYNDROME; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; FACE ERYTHEMA; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH DISORDER; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INFECTION; MALE; MENTAL DISEASE; MYOPATHY; NAUSEA; OSTEOPOROSIS; PETECHIA; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN DEFECT; STRIA; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; BECLOMETHASONE; COLON; CROHN DISEASE; DRUG EVALUATION; ERYTHEMA; FEMALE; HUMANS; ILEAL DISEASES; MALE; MIDDLE AGED; NAUSEA; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 34547496247     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.02.013     Document Type: Article

References (49)

1. MacDermott RP, Lichtenstein GR. Integrating anti-tumor necrosis factor-alpha therapy into the management of Crohn's disease: current and future perspectives. Available from URL: =http://www.medscape.com/viewarticle/419988?src=search (accessed on 17th Feb, 2006).
2. Ardizzone S., and Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs 65 (2005) 2253-2286
3. Viscido A., Aratari A., Maccioni F., Signore A., and Caprilli R. Inflammatory bowel diseases: clinical update of practical guidelines. Nucl Med Commun 26 (2005) 649-655
4. Isaacs K.L., Lewis J.D., Sandborn W.J., Sands B.E., and Targan S.R. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis 11 Suppl 1 (2005) S3-S12
5. MacDonald T.T., DiSabatino A., and Gordon J.N. Immunopathogenesis of Crohn's disease. JPEN J Parenter Enteral Nutr 29 Suppl 4 (2005) S118-S124
6. Mascheretti S., and Schreiber S. Genetic testing in Crohn disease: utility in individualizing patient management. Am J Pharmacogenomics 5 (2005) 213-222
7. Gordon J.N., Di Sabatino A., and Macdonald T.T. The pathophysiologic rationale for biological therapies in inflammatory bowel disease. Curr Opin Gastroenterol 21 (2005) 431-437
8. Feagan BG. What's on the horizon? A view of the management of Crohn's disease over the next decade. Available from URL: http://www.medscape.com/viewprogram/4284_pnt (accessed on 17th Feb, 2006).
9. Munkholm P., Langholz E., Davidsen M., and Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 35 (1994) 360-362
10. Campieri M. New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut 50 Suppl 3 (2002) 43-46
11. Sandborn W.J., and Feagan B.G. Mild to moderate Crohn's disease-defining the basis for a new treatment algorithm. Aliment Pharmacol Ther 18 (2003) 263-277
12. Penner R.M., Madsen K.L., and Fedorak R.N. Postoperative Crohn's disease. Inflamm Bowel Dis 11 (2005) 765-777
13. Siegel C.A., and Sands B.E. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther 22 (2005) 1-16
14. Van Assche G., Vermiere S., and Rutgeerts P. Medical treatment of inflammatory bowel diseases. Curr Opin Gastroenterol 21 (2005) 443-447
15. Aggarwal B.B., Shishodia S., Takada Y., Jackson-Bernitsas D., Ahn K.S., Sethi G., et al. TNF blockade: an inflammatory issue. Ernst Schering Res Found Workshop 56 (2006) 161-186
16. Siddiqui M.A., and Scott L.J. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs 65 (2005) 2179-2208
17. Egan L.J., and Sandborn W.J. Advances in treatment of Crohn's disease. Gastroenterology 126 (2004) 1574-1581
18. Kesisoglou F., and Zimmermann E.M. Novel drug delivery strategies for the treatment of inflammatory bowel disease. Expert Opin Drug Deliv 2 (2005) 451-463
19. Campieri M., Cottone M., Miglio F., Manenti F., Astegiano M., D'Arienzo A., et al. Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. Aliment Pharmacol Ther 12 (1998) 361-366
20. Kumana C.R., Seaton T., Meghji M., Castelli M., Benson R., and Sivakumaran T. Beclomethasone dipropionate enemas for treating inflammatory bowel disease without producing Cushing's syndrome of hypothalamic pituitary adrenal suppression. Lancet 1 8272 (1982) 579-583
21. Friedman S. General principles of medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am 33 (2004) 191-208
22. Hoffmann J.C., and Zeitz M. Treatment of Crohn's disease. Hepatogastroenterology 47 (2000) 90-100
23. Regueiro M.D. Update in medical treatment of Crohn's disease. J Clin Gastroenterol 31 (2000) 282-291
24. Rutgeerts P.J. Conventional treatment of Crohn's disease: objectives and outcomes. Inflamm Bowel Dis 7 Suppl 1 (2001) 2-8
25. Travis S. Advances in therapeutic approaches to ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 7 (2005) 475-484
26. Brookes M.J., and Green J.R. Maintenance of remission in Crohn's disease: current and emerging therapeutic options. Drugs 64 (2004) 1069-1089
27. Lichtenstein G.R., Yan S., Bala M., and Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 99 (2004) 91-96
28. Akobeng A.K., and Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev 1 (2005) CD003715
29. Baert F., Vermeire S., Noman M., Van Assche G., D'Haens G., and Rutgeerts P. Management of ulcerative colitis and Crohn's disease. Acta Clin Belg 59 (2004) 304-314
30. Bajaj J.S., Saeian K., Varma R.R., Franco J., Knox J.F., Podoll J., et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol 100 (2005) 1121-1125
31. Otley A., and Steinhart A.H. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 4 (2005) CD000296
32. Hanauer S.B. Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 20 Suppl 4 (2004) 60-65
33. Moum B. 5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease. Tidsskr Nor Laegeforen 123 (2003) 2565-2567
34. De Jong D.J., Goullet M., and Naber T.H. Side effects of azathioprine in patients with Crohn's disease. Eur J Gastroenterol Hepatol 16 (2004) 207-212
35. Scholmerich J. Which immunosuppressors do you use to treat Crohn's disease and ulcerative colitis? In which order of priority and how worried are you about toxicity?. Inflamm Bowel Dis 4 (1998) 248-252
36. Escher J.C. European Collaborative Research Group on Budesonide in Paediatric IBD. Eur J Gastroenterol Hepatol 16 (2004) 47-54
37. Levine A., Broide E., Stein M., Bujanover Y., Weizman Z., Dinari G., et al. Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children. J Pediatr 140 (2002) 75-80
38. Levine A., Weizman Z., Broide E., Shamir R., Shaoul R., Pacht A., et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease. J Pediatr Gastroenterol Nutr 36 (2003) 248-252
39. Beaven S.W., and Abreu M.T. Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol 20 (2004) 318-327
40. Vermeire S., Van Assche G., and Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 580-586
41. Solem C.A., Loftus Jr. E.V., Tremaine W.J., Harmsen W.S., Zinsmeister A.R., and Sandborn W.J. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 11 (2005) 707-712
42. Cabrera-Abreu J.C., Davies P., and Matek Z. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child 89 (2004) 69-71
43. Lamers C.B., Biemond I., van der Sluys Veer A., and van Hogezand R.A. Assessment of inflammatory activity in Crohn's disease. Neth J Med 45 (1994) 52-54
44. Mahmud N., McDonald G.S., Kelleher D., and Weir D.G. Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease. Gut 38 (1996) 99-103
45. Sachar D.B., Smith H., Chan S., Cohen L.B., Lichtiger S., and Messer J. Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol 8 (1986) 647-650
46. Sachar D.B., Luppescu N.E., Bodian C., Shlien R.D., Fabry T.L., and Gumaste V.V. Erythrocyte sedimentation as a measure of Crohn's disease activity: opposite trends in ileitis versus colitis. J Clin Gastroenterol 12 (1990) 643-646
47. Campieri M., Ferguson A., Doe W., Persson T., and Nilsson L.G. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 41 (1997) 209-214
48. Gross V., Andus T., Caesar I., Bischoff S.C., Lochs H., Tromm A., et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 8 (1996) 905-909
49. Papi C., Luchetti R., Gili L., Montanti S., Koch M., and Capurso L. Budesonide in the treatment of Crohn's disease: a meta-analysis. Aliment Pharmacol Ther 14 (2000) 1419-1428